Understanding the Burden of ACC Through the Eyes of Patients

Completed

Conditions studied: Adenoid Cystic Carcinoma

In brief

This is a comprehensive, cross-sectional study conducted with approximately 40-60 individuals affected by ACC who may know the results of molecular profiling of their tumor. Primary Objectives: * To identify the specific burdens faced by patients with ACC * To compare/contrast the burdens faced by patients with ACC at different disease stages (no evident disease, metastatic disease/watchful waiting, progressive disease)

Key facts

Study ID

NCT04706845

Run by

Ayala Pharmaceuticals, Inc,

People needed

46

Starts

2021-01-11

Expected to finish

2023-08-16

Last updated by the study team

2023-09-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participant must be a person diagnosed with ACC who is 18 years or older
• For patients with metastatic disease; watchful waiting or progressive disease, participants must know the results of molecular profiling of their tumor
• Histologically-confirmed diagnosis of ACC with written proof of disease and molecular profile of tumor provided. This can be a note showing genetic diagnosis from a relevant testing laboratory, physician consult notes, a medical record of diagnosis, or any other single piece of documentation that connects your name/the patient's name with ACC.
• Able to read, write and understand English, Hebrew, Arabic, or Russian
• Able to grant informed consent
• Willing to participate in a 45-to-60-minute telephone interview, including follow up questions (if necessary)

You may not qualify if…

• Inability to meet any of the inclusion criteria

Where it is running

• Engage Health — Eagan, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.